Seroatlas · Human Serome Atlas

LZTS3

Leucine zipper putative tumor suppressor 3

Also known as: KIAA0552, LZTS3_HUMAN, ProSAPiP1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O60299
Gene
LZTS3
Ensembl
ENSG00000088899
Chromosome
20
Canonical length
673 aa
Protein class
Predicted intracellular proteins
Subcellular location
Vesicles
Quaternary structure
Homooligomer

OverviewNCBI Gene

Predicted to enable PDZ domain binding activity. Predicted to be involved in protein homooligomerization; regulation of dendritic spine morphogenesis; and regulation of postsynapse assembly. Predicted to be located in postsynaptic density. Predicted to be active in dendritic spine and glutamatergic synapse. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

673 residues, UniProt reviewed canonical sequence.

>O60299|LZTS3
     1  MAKLETLPVR ADPGRDPLLA FAPRPSELGP PDPRLAMGSV GSGVAHAQEF AMKSVGTRTG
    61  GGGSQGSFPG PRGSGSGASR ERPGRYPSED KGLANSLYLN GELRGSDHTD VCGNVVGSSG
   121  GSSSSGGSDK APPQYREPSH PPKLLATSGK LDQCSEPLVR PSAFKPVVPK NFHSMQNLCP
   181  PQTNGTPEGR QGPGGLKGGL DKSRTMTPAG GSGSGLSDSG RNSLTSLPTY SSSYSQHLAP
   241  LSASTSHINR IGTASYGSGS GGSSGGGSGY QDLGTSDSGR ASSKSGSSSS MGRPGHLGSG
   301  EGGGGGLPFA ACSPPSPSAL IQELEERLWE KEQEVAALRR SLEQSEAAVA QVLEERQKAW
   361  ERELAELRQG CSGKLQQVAR RAQRAQQGLQ LQVLRLQQDK KQLQEEAARL MRQREELEDK
   421  VAACQKEQAD FLPRIEETKW EVCQKAGEIS LLKQQLKDSQ ADVSQKLSEI VGLRSQLREG
   481  RASLREKEEQ LLSLRDSFSS KQASLELGEG ELPAACLKPA LTPVDPAEPQ DALATCESDE
   541  AKMRRQAGVA AAASLVSVDG EAEAGGESGT RALRREVGRL QAELAAERRA RERQGASFAE
   601  ERRVWLEEKE KVIEYQKQLQ LSYVEMYQRN QQLERRLRER GAAGGASTPT PQHGEEKKAW
   661  TPSRLERIES TEI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LZTS3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.62
Highest tissue expression
175 nTPM

Expression across tissuesHPA

Tissue

  • cerebellum: 175 nTPM
  • cerebral cortex: 114 nTPM
  • basal ganglia: 94 nTPM
  • amygdala: 57 nTPM
  • hippocampal formation: 56 nTPM
  • retina: 50 nTPM

Single-cell type

  • rod photoreceptor cells: 64 nCPM
  • lacrimal acinar cells: 63 nCPM
  • brain excitatory neurons: 61 nCPM
  • brain inhibitory neurons: 52 nCPM
  • salivary ionocytes: 52 nCPM
  • salivary acinar cells: 41 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • basal ganglia: 186 nTPM
  • cerebral cortex: 180 nTPM
  • hippocampal formation: 159 nTPM
  • amygdala: 139 nTPM
  • cerebellum: 139 nTPM
  • white matter: 132 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.23
gnomAD pLI
1
gnomAD missense Z
1.75
DepMap mean gene effect
-0.02
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LZTS3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LZTS3 as an antibody target. Whether an autoantibody or antibody against LZTS3 could matter depends on whether native LZTS3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LZTS3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label LZTS3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/LZTS3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...